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Summary. Following myelo-ablative treatment and 
allogeneic bone marrow transplantation (BMT) in 
chronic myelogenous leukemia (CML) histopathological 
features assumed to exert a sienificant i m ~ a c t  on 
engraftment have been rarely inve;igated systekatically. 
This review is focused on immunohistochemical and 
morphometric techniques involving nucleated erythroid 
precursors, resident macrophages and their various 
subsets, megakaryocytes and finally argyrophilic 
(reticulin-collagen) fibers. Regarding standardized 
intervals of examination in the postgraft sequential 
trephine biopsies a pronounced reduction in cellularity 
was obvious and accompanied by a decrease in the 
quantity of erythro- and megakaryopoiesis. A significant 
correlation between the number of erythroid precursors 
and CD68+-macrophages could be determined in the 
areas of regenerating hematopoiesis. This finding is in 
keeping with the important functional role of the 
centrally localized mature macrophages during 
erythropoiesis. A relevant pretransplant reduction of the 
red cell lineage and an early to advanced reticulin 
fibrosis were correlated with a low hemoglobin leve1 
(anemia) and splenomegaly and furthermore associated 
with a significant delay to reach transfusion 
independence. This  result was supported by 
corresponding findings in biopsy specimens performed 
shortly after day 30 following BMT (standard interval 
for assessment of engraftment). Samples revealed an 
enhancement of fiber density and a conspicuous decrease 
in the amount of erythropoiesis in the small fraction of 
patients who did not conform with the usually accepted 
criteria for successful hematopoietic reconstitution. 
Considering the compartment of histiocytic reticular 
cells the recurrence of Pseudo-Gaucher cells (PCGs) in 
the engrafted donor marrow was remarkable and most 
prominently expressed in the first two months following 
BMT. This feature was presumed to be functionally 
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linked with a pronounced degradation of cell debris in 
the seque1 of myelo-ablative therapy (scavenger 
macrophages). According to planimetric measurements 
in the postgraft bone marrow the atypical dwarf-like 
CD61+-megakaryocytes characteristic for  CML 
disappeared. On the other hand, normalization of 
megakaryocyte size and nuclear lobulation were absent 
in sequential examination of the few patients developing 
a leukemic relapse. In a number of patients with 
manifest myelofibrosis at onset, an initial regression 
after BMT was followed by an insidiously occurring 
retrieval which was concentrated on the areas of 
reconstituting hematopoiesis. Similar to its relevant 
pretransplant association the postgraft reappearance of 
myelofibrosis was significantly correlated with the 
quantity of CD61+-megakaryocytes. Altogether a 
number of histological features in the pre-and postgraft 
bone marrow exhibited significant correlations with each 
other and thus indicated functional relationships. 
Moreover, quantity of erythropoiesis and amount of 
reticulin fibers (myelofibrosis) exerted a significant 
impact on engraftment status. 
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lntroduction 
Bone marrow and stem cell transplantations are now 
a generally accepted mode of therapy with the option to 
cure various malignancies including malignant 
lymphomas, acute and chronic leukemias and multiple 
myeloma. Although in the past decades considerable 
progress has been made conceming the biology of this 
procedure, until now little information exists about 
morphological changes associated with pretransplant 
myelo-ablative therapy and postgraft reconstitution of 
normal hematopoiesis (Sale and Buckner, 1988; Van den 
Berg et al., 1990; Rousselet et al., 1996). With exception 
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of myelofibrosis (McGlave et al., 1982; Rajantie et al., 
1986; Sol1 et al., 1995), there is hardly any knowledge 
about specific alterations affecting the other constituents 
of the bone marrow, i.e. the parenchymal 
(hematopoiesis) or mesenchymal (stroma) compartment 
(Rousselet et al., 1996; Hurwitz, 1997). Because of their 
putative influence on the complex functional network 
composing the microenvironment which exerts a 
significant impact on hematopoietic recovery and thus 
engraftment parameters (Mayani et al., 1990; Wilson and 
Tavassoli, 1994; Domenech et al., 1998), this point 
merits special attention. Amongst others this lack of 
relevant findings may have been generated by the 
reluctance of many clinicians to perform sequential bone 
marrow trephine biopsies instead of or besides aspirates 
in the first weeks following transplantation or at short 
intervals during the critica1 phase of hematopoietic 
reconstitution. On the other hand, an appropriate 
evaluation of bone marrow features evolving during the 
postgraft period may cast  new perspectives on 
pathomechanisms possibly associated not only with 
successful,  but also with delayed or even failing 
hematopoietic regeneration (Martin, 1992). In this 
context morphological parameters responsible for 
homing and accordingly posttransplant transfusion 
independence may be unraveled. Since relatively few 
data on postgraft bone marrow histopathology 
(Rousselet et al., 1996) in relation to the wealth of 
clinical findings (Gratwohl et al., 1993; McGlave et al., 
1994; Appelbaum et al., 1995; Beelen et al., 1995; Clift 
and Anasetti, 1997; Lamparelli et al., 1997; Van Rhee et 
al., 1997; Dini et al., 1998; Hansen et al., 1998) are 
available, the present review is focused on our own 
experiences concerning allogeneic bone marrow 
transplantation (BMT) in patients with Philadelphia 
chromosome-positive (Phl+) chronic myelogenous 
leukemia (CML). 
Erythropoiesis and macrophages 
Persuasive evidence has been produced that in the 
CML bone marrow the amount of nucleated erythroid 
precursor cells is not only adversely correlated with the 
pretransplant fiber content (Thiele et al., 1993a), but also 
significantly linked with the quantity of CD68+- 
macrophages (Thiele et al., 1999, 2000a). Mature 
resident. macrophages of the normal bone marrow are 
usually characterized by their peculiar histotopography 
implying a distinctive functional role in the regulation of 
hematopoiesis (Rich, 1986; Wang et al., 1992; Hanspal, 
1997). Histiocytic reticular cells establish an intimate 
spatial and functional contact with erythropoiesis where 
their central localization creates a specific anatomic unit 
the erythropoietic islet (Bernard, 1991). These specific 
features  play a pivotal role in commitment and 
differentiation of progenitor cells of the red lineage 
towards erythroblastic maturation (Gregory and Eaves, 
1978). On the other hand these remarkable groupings of 
erythroid precursors are very small and greatly dispersed 
in the CML bone marrow (Fig. la,b). According to their 
myelo-monocytic progeny in CML patients the resident 
bone marrow macrophages carry the ph l+  or a 
corresponding bcrlabl gene translocation (Golde et al., 
1977; Bhatia et al., 1995; Thiele et al., 1998) like the 
erythroblasts (Haferlach et al., 1997). Although in the 
past decades a controversia1 discussion has emerged 
about the exact functional implication of the central- 
resident macrophages, a number of experimental data 
were accumulated concerning their involvement in the 
degradation of the expelled erythroblastic nuclei. Further 
activities include the presumed turnover of iron and 
other ill-defined metabolites that are released by this 
breakdown and the production of erythropoietin (Vogt et 
al., 1989; Ponka et al., 1998; Meyron-Holtz et al., 1999). 
Following BMT the macrophage lineage deserves 
special attention not only for the regulation of 
erythropoiesis,  but for the restitution of normal 
hematopoiesis (Thiele et al., 2000a). When focusing on 
the postgraft bone marrow and those areas harbouring 
regenerating erythropoiesis (Fig. lc-e), a significant 
relationship between the number of CD68+-macrophages 
and erythroid precursor cells is calculable. Starting about 
9 to 10 days after BMT (endpoint 2 in Table 1) a variable 
grouping of tiny to small erythropoietic islets is 
recognizable (Fig. l c ) .  Normally after one month 
postgraft erythropoiesis is characterized by extensive 
erythroid islets containing centrally localized stellate 
macrophages (Fig. Id). Regeneration of the red cell 
lineage is completed by showing features resembling the 
normal bone marrow (Fig. l e ) ,  but contrasting 
significantly its inconspicuous appearance in the pregraft 
specimens (compare Fig. l b  with Fig. le). In a number 
of patients up to six posttransplant biopsies were carried 
out which readily demonstrate the progressive recovery 
of erythropoiesis following myelo-ablative treatment and 
BMT (Fig. 2). A relevant reduction in the amount of 
erythropoiesis was significantly correlated with a low 
leve1 of hemoglobin (hematocrit) in the pretransplant 
bone marrow examinations (Thiele et al., 1993a, 1999) 
and according to generally accepted clinical findings 
suggested a later stage of the disease process (Cortes et 
al., 1997; Savage et al., 1997; Thiele et al., 2000a). 
Furthermore, this adverse constellation of morphological 
and laboratory data was significantly related to a delayed 
engraftment (transfusion independence mean 37 days 
versus 29 days) as shown in Table 2 for the quantity of 
Fig. 1. Erythropoiesis (anti-glycophorin C immunostaining) in the pre-and postgraft bone marrow in patients with CML. a and b. Small and dispersed 
erythroid islets characterize the pregraft bone marrow. c. About 17 days after BMT there is an initial reconstitution of small to medium-sized clusters of 
erythropoiesis. d. Completed erythroid recovery is shown by extensive islets containing many stellate CD68+-macrophages. e. Large and partially 
confluent groupings of erythroid precursors after successful engraftment (compare with pregraft erythropoiesis - b). a, d, x 370; b, c, e, x 420 
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erythroid precursors in our two cohorts of patients. In al., 1993; Appelbaum et al., 1995; Beelen et al., 1995; 
this context supportive findings were additionally Clift and Anasetti, 1997). Concerning transfusion 
derivedfromthecalculationoferythroidprecursorcell independence a successful engraftment was 
numbers at certain postgraft endpoints following day 30 characterized by a significantly higher amount of 
as the standard check point (Martin, 1992; Gratwohl et erythropoiesis in comparison to a delayed or failing 
hematopoietic reconstitution (Table 2). 
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Flg. 2. Evolution of erythropoiesis and reticulin Rbers in the course of 
BMT in patients with dmerent engraftment status. 
Macrophages and their subpopulations 
In addition to their clonal transformation in CML 
(Golde et al., 1977) resident-mature CD68+-bone 
marrow macrophages (Fig. 3a) represent endcells 
according to cell kinetics (Titius et al., 1994). Histiocytic 
reticular cells are supposed to participate specifically in 
the expansion of the leukemic cell clone and have been 
suggested to contribute significantly to the 
disarrangement of the microenvironmental function 
recognizable in this disorder (Bhatia et al., 1995). 
Moreover, this cell lineage is characterized by a striking 
heterogeneity of differentiation and therefore a variable 
cytological appearance. Prominent subsets include a 
population showing an expression of a-D-galactosyl 
residue-binding carbohydrates on their surface (Fig. 3b) 
which occasionally reveal an engulfment of other 
hematopoietic cells (Fig. 3c). In keeping with 
experimental findings this reactivity is compatible with a 
Table 1. Endpoints of bone manow examinations at standardized intewals of about 20 days following BMT for Phl+-CML in 125 patients. 
Morphometric analysis of parameters ( m m S D )  was carried out per m& total bone manow area and also per hematopoiesis (in brackets). The 
macrophage population included certain subsets and their relative frequency (%) was calculated. One patient may have up to six sequential biopsies. 
ENDPOINTS 
Before BMT BMT After BMT 
(1 (day 0) (2) (3) (4) (5) 
Intervals (days) mean~SD 
No. of patients 
Cellularityíhematopoiesis (median - %) 
Ret4Of+-erythroid precursors x 102 (mmq 
Pseudo-Gaucher cells (% present) 
Iron-laden macrophages (% present) 
Fibers (i x 1 @/mmq 
Flg. 3. Macrophages in the pre-and postgrait bone marrow in patients with CML. a. Before BMT there is a large number of randomly dispersed CD68+- 
macrophages with a conspicuow irregular stellate shape. b. A fracüon of the macrophage population reveals a positive staining with the lectin BSA-I 
(acüvated subset) and some of these (c) show an engulfment of hematopoietic ceils (anow heads). d. Postgraft bone marrow is characterized by many 
CD68+-macrophages including several subsets. e. PGCs (CD68 immunostaining) with prominent clustenng also reveal a distincüve BSA-I reacüvity (1) 
or distincthre PAS staining (g) conesponding wlth an acthmted population. h. Following BMT and transfusion therapy many hisüocyüc reticular cells are 
laden with iron-positive deposits. a, d, x 170; b, c, e, f, x 370 
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state of activation (Adams and Hamilton, 1984; Irimura 
et al., 1987; Keller et al., 1993). This feature can be 
easily identified by proper histochemical staining with a 
corresponding lectin from Bandeiraea (Griffonia) 
simplicifolia isotype 1-B4 (BSA-1) specific for this sugar 
(Maddox et al., 1982; Tabor et al., 1989; Warfel and 
Zucker-Franklin, 1992; Baldus et al., 1995). Another 
fraction of macrophages is detectable by exhibiting the 
peculiar phenomenon of acquired lipidosis including 
Pseudo-Gaucher cells (PGCs) and sea-blue (blue- 
pigmented) histiocytic reticular cells (Gerdes et al., 
1969; Rosner et al., 1969; Lee and Ellis, 1971; Hayhoe 
et al., 1979; Kelsey and Geary, 1988; Georgii et al., 
1990; Thiele et al., 1992, 1999; Buesche et al., 1997). 
Finally, there is the relative small subset of iron-laden 
macrophages which in CML, compared to the normal 
bone marrow, displays a greatly reduced amount of 
stainable granules (Cervantes et al., 1984; Sokal and 
Sheerin, 1986; Thiele et al., 1999, 2000a). Following 
myelo-ablative regimens and BMT quantification of the 
engrafted total CD68+- and BSA-I+-macrophage 
population at standardized endpoints, no significant 
differences in relation to the pretransplant specimens is 
disclosed (Table 1). However, pre- and posttransplant 
changes in cellularity have to be regarded, since 
compared to the normal bone marrow and calculated. @r 
hematopoiesis (Thiele et al., 1999) a 40 to 50% decrease 
in incidence is detectable in the postgraft specimens 
shortly after BMT (Table 1). These features may be 
related to the initiation of erythropoietic reconstitution 
and therefore functional implications of the macrophage 
system which have been outlined before (Thiele et al., 
2000b,c). Moreover, in a number of patients the so- 
called activated (BSA-1+) fraction, including PGCs and 
in particular also the iron-storing histiocytic reticular 
cells reveal a borderline to pronounced increase (Fig. 3d- 
h). This enhancement also implies a conspicuous 
clustering of PGCs (Fig. 3e-g) and coarse granular iron 
deposits in many macrophages (Fig. 3h). This prevalence 
of iron-laden histiocytic reticular cells is opposed to their 
scarcity and weak staining reaction in the pretransplant 
bone marrow samples and probably has to be regarded as 
the seque1 of intensive transfusion therapy (Rousselet et 
al., 1996; Thiele et al., 2000b). On the other hand, 
reappearance of PGCs seems to be a relatively early 
event, since it is recognizable already at day 9 following 
BMT (Table 1). This retrieval is further related to their 
former presence in the pretransplant bone marrow of the 
recepient. It is noteworthy that PGCs did not indicate a 
relevant Phl+ (bcrlabl) cell clone or a leukemic relapse 
in our cohort of patients under study and displayed a 
progressive decline in frequency during the prolonged 
posttransplant period (Thiele et al., 2000~). The in vitro 
finding of a functionally activated state of the BSA-I+- 
macrophage population (Adams and Hamilton, 1984) 
gains further support by a corresponding staining 
capacity of PGCs including the expression of an 
identical carbohydrate-binding (Thiele et al., 1999). It is 
noteworthy that PGCs are not only described in CML, 
but in a variety of hematopathologic disorders ranging 
from acute leukemia (Hayhoe et al., 1979) to thalassemia 
(Zaino et al., 1972) and congenital dyserythropoietic 
Table 2. Significant relationships (pr 0.05) belween pre- and posttransplant quantity (mean~SD) of marrow features corresponding with hematological 
reconstitution at certain endpoints (compare with Table 1). Values listed are per total marrow area and per hematopoiesis (in brackets). As standard the 
generally accepted engraftment parameter of transfusion independence at day 30 following BMT was chosen as cut-off point. 
ENDPOINT OF BIOPSY ENGRAFTMENT STATUS No. OF PATIENTS ERMHROID PRECURSORS x102 (mm2) FIBERS (ix102/mm2) 
(1) before BMT 
(3) after BMT 
(4) after BMT 
successful 
delayed 
successful 
delayed 
successful 
delayed 
7 
Fig. 4. Megakaryopoiesis (CD61+ immunostaining) in the pre- and postgraft bone marrow in patients with CML. a. Micromegakaryocytes characterize 
the bone marrow before BMT. b. In the postgraft specimens onset of megakaryocyte recovery is indicated by small groups of medium-sized cells some 
of them revealing dysplastic features and subsequently an increased lobulation of their nuclei (c). d. Successful engraftment is associated not only with 
a prominent assembly of large megakaryocytes, but also with extensive erythropoietic islets (in the background). e. Leukemic relapse shows atypical 
megakaryocytes comparable with pregrafl samples (compare with pregraft megakaryocytes - a) and a dense (granulocytic) cell population (in the 
background). x 370 
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anemia (Enquist et al., 1972; Van Dorpe et al., 1973). 
Furthermore, crystal-storing histiocytes in multiple 
myeloma or lympho-plasmacytoid lymphoma may adopt 
the appearance of PGCs, but, however, are characterized 
by a deposition of hydrophobic proteins with a needle- 
like structure (Schaefer, 1996). In CML, unlike true 
Gaucher's disease there is a significantly expanded bulk 
of granulocytes (Kampine et al., 1967) presenting a mass 
of glycolipids which the activated and competent 
macrophage cell compartment is unable to catabolize 
despite a normal or even increased lysosomal enzyme 
activity (Kattlove et al., 1969; Dosik et al., 1972; 
Hayhoe et al., 1979). Consequently, by regarding 
glycosyl-ceraminidase reactivity it is feasible to 
distinguish true Gaucher-cells from PGCs in the few 
patients suffering from both conditions (Shinar et al., 
1982). The continuous repopulation of the bone marrow 
by macrophages including PGCs depends completely on 
monocytes which are derived from the engrafted marrow 
pool. Contrasting a pertinent report where PGCs were 
detectable more than one year following BMT and 
associated with a leukemic relapse (Anastasi et al., 
1998), in our series of patients this cell lineage was 
predominently observed in the first two months after 
BMT (Table 1). Considering their presence in a number 
of different hematological conditions this temporary 
occurrence was related to an increased cell turnover 
assumed to result from a scavenger function after 
myeloablative therapy (Thiele et al., 2000~). The two 
patients showing PGCs almost one year after BMT 
(Table 1) yielded no evidence for a significant Phl+ cell 
Flg. 5. Evolution of megakaryocyie size and frequency in the course of 
BMT ki two patients showing &her a failure to engrafl or a leukemic 
relapoe aíter delayed engraftment. 
clone or leukemic relapse during obsewation time. 
Megakaryocytes and myelofibrosis 
Although extensive experimental and morphological 
studies have significantly increased our knowledge about 
the complexity and diversity of the functional 
interactions between abnormal megakaryopoiesis and 
pathogenesis of myelofibrosis (Reilly, 1992; Kimura et 
al., 1995; Martyré, 1995), hardly any data are available 
relating to these features after BMT. Moreover, 
compelling evidence has been produced that in CML 
megakaryopoiesis is characterized by a prevalence of 
atypical micro- or dwarf forms (Burckhardt et al., 1984; 
Georgii et al., 1990; Thiele and Fischer, 1991; Bartl et 
al., 1993; Dickstein and Vardiman, 1993; Thiele et al., 
1999) exhibiting dense hypolobulated nuclei (Fig. 4a). A 
number of studies including morphometry, flow 
cytometry, determination of DNA content and 
cytogenetic analysis were in keeping with the 
assumption that in CML opposed to the normal bone 
marrgw, megakaryocytes are not only very small, but 
also hypoploid (Ishibashi et al., 1986; Tomer et al., 1989; 
Ridell et al., 1990; Thiele et al., 1990, 2000a; Woods et 
al., 1990; Nafe et al., 1991). In this context it has been 
convincingly demonstrated that megakaryocyte size was 
significantly associated with the degree of lobulation and 
ploidy (Levine et al., 1982). Furthermore, fluorescence 
in situ hybridization reveals that a normalization of 
megakaryocyte size following interferon therapy of 
CML patients was correlated with a loss of the bcrlabl 
translocation sites and therefore indicated recovery of 
normal hematopoiesis (Thiele et al., 1997a). Concerning 
BMT patients with a failing or delayed hematopoietic 
reconstitution had a pretransplant higher count for 
CD61t megakaryocytes (megakaryocyte-rich subtypes 
of CML). Comparable findings were detectable 
regarding the platelet count (Thiele et al., 2000d). 
Cytological abnormalities in the early posttransplant 
period especially affecting the megakaryopoiesis were 
described to exhibit a dysplastic aspect (Rousselet et al., 
1996; Hurwitz, 1997). After myelo-ablative therapy and 
BMT quantity of CD61+-megakaryopoiesis including 
precursor cells like ~romeeakarvoblasts and 
megakaryoblasts decreasedssigniñ~antly -(Table 1). This 
reduction was observable immediatelv after BMT and 
associated with severe thrombocytope&a which required 
appropriate supportive therapy. Considering normal bone 
marrow samples and platelet transfusion independence, 
the majority of patients achieved a substantial 
megakaryocyte regeneration between the second and 
third month following BMT (Thiele et al., 2000d). 
Posttransplant recovery, i.e. growth of megakaryopoiesis 
became explicitly obvious in patients that had severa1 
r 
Flg. 6. Myelofibrosis in the pre- and postgraft bone marrow in patients with CML. a. Early reticulin fibrosis before BMT. b. Retrieval of reticulin fibers in 
the areas of regenerating hematopoiesis of poctgrafl specimens after about three months. c. Failed engraitment with absence of hematopoietic cells, 
but with discrete reticulin fibrosis. d. Successful engraftment showing no relevant reticulin fibers and normal-sized megakaryocytes (arrows) 
comparable with Fig. 4d. x 210 
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examinations performed at short intervals (Fig. 5). 
However, opposed to the atypical small megakaryocytes 
specific for CML (Fig. 4a), postgraft megakaryopoiesis 
revealed a predominance of a normal-sized population 
(Fig. 4b-d). Reconstitution of this lineage started with 
small clusters of medium-sized cells showing moderate 
nuclear lobulation, some of them with myelodysplastic 
features (Fig. 4b). The latter increased gradually (Fig. 
4c) and finally merged into large megakaryocytes 
consistent with a state of successful engraftment (Fig. 
4d). This phenomenon was significantly associated with 
corresponding cytogenetic-molecularbiological findings. 
Contrasting successful engraftment with an absence of a 
relevant residual bcrlabl-positive cell population, in 
patients with a leukemic relapse or a failure to engraft, a 
conspicuous recurrence of these abnormal micro- 
megakaryocytes was detectable (Fig. 4e). Evolution of 
these features may be readily demonstrated in sequential 
biopsies regarding size and frequency of megakaryocytes 
in the course of BMT (Fig. 5). Altogether these findings 
underline the significant relationship between 
megakaryocyte size, nuclear lobulation and ploidy as the 
most specific hallmark for the CML bone marrow 
(Levine et al., 1982). A similar relationship has been 
postulated between the number of megakaryocytes 
including its precursor cell fraction and the development 
of myelofibrosis (Buhr et al., 1992; Thiele et al., 199%). 
These observations led to the generally accepted concept 
that an inappropriate intramedullary release of certain 
growth factors from the atypical megakaryopoiesis 
stimulates the proliferation of non-clonally transformed 
fibroblasts and thus mediates an enhanced deposition of 
interstitial and basement membrane collagen (Greenberg 
et al., 1978; Golde et al., 1980; O'Brien et al., 1988; 
Kimura et al., 1995). These data are able to explain the 
frequently detectable histotopographical proximity 
between abnormal megakaryocytes and the ensuing 
network of reticulin fibers and also the significant 
correlations between number of megakaryocytes and its 
precursor fractions with fiber density (Thiele et al., 
1993b, 1997b, 2000a). Posttransplant bone marrow 
studies provide supportive findings, because there is a 
significant association between number of 
megakaryocytes and retrieving fibrosis in the areas of 
reconstituting hematopoiesis (Fig. 6b). The assumption 
that normal megakaryocytes derived from the engrafted 
donor bone marrow are capable of growth factor 
secretion and fibroblast stimulation is in keeping with 
corresponding in vitro data on isolated and enriched 
megakaryocytes from healthy control patients (Schmitz 
et al., 1995). At this point it should be discussed whether 
and to what extent the pretransplant conditioning 
regimens generate space or microenvironmental niches 
for the homing and reconstitution of engrafted bone 
marrow cells. The question about efficiency of treatment 
arises which could have failed to ablate totally al1 cell 
populations, i.e. fibroblasts, which may be more resistant 
(Salomon e t  al., 1990;  Domenech et al., 1998). 
Experimental findings are in line with an increased 
capacity of marrow fibroblasts derived from CML 
patients concerning growth and collagen synthesis 
(Yonekura et al., 1985). Therefore, it is tempting to 
speculate that stimulated non-clonal fibroblasts of the 
recipient patient responsible for pregraft myelofibrosis 
may have partially survived (chimerism) and therefore 
could exert an enhancing effect on the cytokine-mediated 
fibrillogenesis in the postgraft bone marrow. 
Myelofibrosis and engraftment 
Controversy and discussion still persists regarding 
not only the impact of pretransplant myelofibrosis on 
postgraft hematopoietic reconstitution (Rajantie et al., 
1986), but also a possible resolution or retrieval of 
fibrosis in the posttransplant period (McGlave et al., 
1982; Rousselet et al., 1996; Thiele et al., 2000). 
Currently there is much speculation that myelofibrosis 
may present an impediment to successful engraftment by 
exerting an inverse influence on the complex functional 
network of the bone marrow microenvironment 
preventing an undisturbed homing of stem cells 
(Domenech et al., 1998). Opposed to this concern, recent 
results obtained in allogeneic BMT and stem cell 
transplantation involving idiopathic (primary) and 
postpolycythemic myelofibrosis with myeloid 
metaplasia are very promising (Guardiola et al., 1997, 
1999). Regarding myelofibrosis in CML patients and 
impairment of hematopoietic regeneration the situation 
becomes even more complicated, because two 
consecutively published studies which were apparently 
derived from the same group reported divergent findings 
(Rajantie et al., 1986; Soll et al., 1995). However, in this 
context a number of caveats have to be taken into 
account especially related to the selection of patients and 
methodology (Thiele et al., 2000e). It is imperative to 
discuss that contrasting the results listed in Table 1 
quantification of the fiber content was usually performed 
by a rather cmde semiquantitative scoring (Bauermeister, 
1971) which allows wide ranges of gradings in 
borderline and early myelofibrosis. Because 
myelofibrosis is considered not a static, but a dynamic 
process standardized endpoints of examinations covering 
similar intervals as carried out in the evaluations shown 
in Table 1 are mandatory. Until now these basic 
guidelines of determination have not been always or 
explicitly regarded in the pertinent literature. This 
shortcoming is enhanced by the failure to provide some 
information about the time gap between the first 
diagnostic biopsy showing presence of myelofibrosis 
and the date of BMT which seems to be very important 
for the assessment of postgraft evolution of fibrosis and 
transplant outcome (Goldman et al., 1993). Finally, in 
the few studies related to this subject a variety of 
hematological conditions were included ranging from 
CML to malignant lymphomas at significantly different 
stages of disease progression (Soll et al., 1995). In 
consideration of these inconsistencies which preclude a 
straightforward comparison of data, it is not astonishing 
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that pretransplant myelofibrosis was found to delay the 
time for achievement of platelet transfusion 
independence by a rather neglectable period of three 
days (Sol1 et al., 1995). Moreover, it has been recorded 
that during the posttransplant period there was a reversal 
of severe bone marrow fibrosis and osteosclerosis 
(McGlave et al., 1982). These results are inconclusive 
and warrant revision by applying more elaborate 
methods of determination, i.e. morphometry and defined 
intervals between measurements. Morphometric analysis 
revealed that according to standard clinical criteria 
(Martin, 1992; Beelen et al., 1995) in our series of 
patients with an early to advanced reticulin 
myelofibrosis (Fig. 6a) a significant delay or even failure 
of engraftment occurred (mean 36 days versus 27 days). 
Supportive evidence of these results was produced by 
calculating the fiber content at different endpoints of the 
pre- and particularly also posttransplant period following 
day 30 as cut-off point. Not only did pregraft reticulin 
fiber density (endpoint 1) display a relevant correlation 
with splenomegaly (Thiele et al., 1993b, 1999, 2000a), 
but it also exerted an influence on engraftment 
parameters. Additional measurements performed at 
endpoints 3 and 4 (Table 1) exhibited confirmative 
findings concerning the s tatus of hematopoietic 
reconstitution (Table 2). In this regard, speculations 
about an insufficient marrow space or inadequate 
functional microenvironment to provide successful 
postgraft development of hematopoiesis should be re- 
evaluated (Domenech et al., 1998). In addition to a 
disarrangement of the cellular compartment with a 
patchy regeneration of hematopoiesis in the early 
posttransplant period there is also a conspicuous so- 
called scleredema of the interstitial space (Van den Berg 
et al., 1990; Hurwitz, 1997). Moreover, in a number of 
patients with a pretransplant myelofibrosis (Fig. 6a) an 
insidious retrieval of reticulin fibers was detectable in 
the areas of regenerating hematopoiesis about three to 
four months after BMT (Fig. 6b). This feature was again 
related to a delayed transfusion independence and 
especially evident in patients with several sequential 
biopsies in the posttransplant period (Fig. 5). A 
definitely failing engraftment was frequently associated 
with manifest fibrosis and absence of a relevant amount 
of hematopoietic cells (Fig. 6c) opposed to the majority 
of patients with no postgraft increase in reticulin and 
completed regeneration of hematopoiesis (Fig. 6d). The 
impression of a sustained reduction of myelofibrosis in 
the postgraft bone marrow specimens (McGlave et al., 
1982) may be probably also generated by focusing on 
the total marrow area including proteinaceous edema and 
adipose tissue and sparing the relevant areas occupied by 
hematopoiesis (Fig. 6b-d ). Regarding these facts, the 
disparate reports on a posttransplant regression and 
retrieval of reticulin fibrosis should be re-evaluated more 
critically (Thiele et al., 2000e). 
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